Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07088757
PHASE4

Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis

Sponsor: Changhai Hospital

View on ClinicalTrials.gov

Summary

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a widely used procedure for diagnosing and treating pancreatic and biliary diseases. Despite its benefits, ERCP carries a risk of post-procedure pancreatitis (PEP), which occurs in approximately 12.2% of cases and can significantly increase healthcare costs and patient morbidity. Preventing PEP is crucial for improving patient outcomes and reducing the economic burden of ERCP. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, have been shown to be effective in reducing the incidence of PEP when administered rectally before ERCP. The standard dose recommended by guidelines is 100mg, which has been associated with a significant reduction in PEP rates. However, higher doses of NSAIDs can increase the risk of adverse events, including gastrointestinal bleeding and renal impairment. Therefore, there is a need to determine whether a lower dose can provide similar benefits without increasing these risks. This multicenter, non-inferiority, double-blind, randomized controlled trial will be conducted in China. Participants will be adults aged 18 or older scheduled for ERCP. They will be randomly assigned in a 1:1 ratio to either the low-dose (50mg) or standard-dose (100mg) indomethacin group. The intervention will be administered rectally 30 minutes before the ERCP procedure. The study will follow a double-blind design, ensuring that both patients and investigators are unaware of the treatment allocation. The results of this trial could significantly influence clinical practice by providing evidence on the effectiveness of a lower dose of indomethacin in preventing PEP. This could lead to a reduction in the risk of adverse events associated with higher doses and potentially decrease healthcare costs without compromising patient safety. By optimizing the dosing of indomethacin, this study aims to improve the safety and cost-effectiveness of ERCP procedures.

Official title: Low-Dose Versus Standard-Dose Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Multicentre, Non-Inferiority, Double-Blind, Randomised, Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1366

Start Date

2025-09-15

Completion Date

2026-12-01

Last Updated

2025-11-18

Healthy Volunteers

No

Interventions

DRUG

standard dose indomethacin

Patients randomized to this intervention receive 100mg indomethacin suppositories within 30 min before ERCP.

DRUG

low dose indomethacin

Patients randomized to this intervention receive 50mg indomethacin suppositories within 30 min before ERCP.

Locations (12)

Changhai Hospital

Shanghai, China

Ruijin Hospital

Shanghai, China

Shanghai General Hospital

Shanghai, China

Affiliated Hospital of Jiaxing University

Zhejiang, China

Dongyang People's Hospital

Zhejiang, China

First Affiliated Hospital of Ningbo University

Zhejiang, China

Jinhua Central Hospital

Zhejiang, China

People's Hospital of Quzhou

Zhejiang, China

Shaoxing People's Hospital

Zhejiang, China

Sir Run Run Shaw Hospital

Zhejiang, China

Taizhou Enze Medical Center Group

Zhejiang, China

Zhuji People's Hospital of Zhejiang Province

Zhejiang, China